In this new article, Niels van de Donk & Sonja Zweegman discuss recent results from the DREAMM-7 & DREAMM-8 trials of belantamab mafodotin-based triplet regimens, in the context of the evolving therapeutic landscape for RRMM: nature.com/articles/s4157…

In this new Review, Jeesun Yoon & Do-Youn Oh provide an update on the current landscape of HER2-targeted therapies beyond breast cancer: nature.com/articles/s4157…

In this new article, we summarize results from the HD21 trial of first-line BrECADD vs eBEACOPP for advanced-stage classical Hodgkin lymphoma: nature.com/articles/s4157…

In a Research Highlight now published online, we discuss the results of the innovaTV 301 trial that led to the approval of tisotumab vedotin in patients with previously treated recurrent and/or metastatic cervical cancer nature.com/articles/s4157…

In a Review now published online, Julia Chen, Ludvig Larsson, Alexander Swarbrick & Joakim Lundeberg provide an overview of the use of single-cell and spatial profiling tools in oncology and discuss potential applications in patient management: nature.com/articles/s4157…

Check this fantastic Review in our sister journal Nature Reviews Genetics , which beautifully complements a Review published in our journal, also from Samuel Bakhoum nature.com/articles/s4157…

In a Research Highlight now published online, we discuss the results of the phase III ETER701 trial of anti-angiogenic agent + ICI + chemotherapy in extensive-stage small-cell lung cancer nature.com/articles/s4157…

On July 30th, FDA Oncology approved daratumumab & hyaluronidase + bortezomib, lenalidomide & dexamethasone for induction and consol in pts w newly diagnosed multiple myeloma eligible for autol stem cell transpl - based on results from PERSEUS, covered in: nature.com/articles/s4157…

The FDA has granted accelerated approval to afamitresgene autoleucel (an autologous MAGE-A4-directed TCR-engineered T cell product) for advanced stage synovial sarcoma, based on data from the SPEARHEAD-1 trial: fda.gov/drugs/resource…. Also see: nature.com/articles/s4157…

Yesterday, the FDA approved vorasidenib for patients aged ≥12 years with grade 2 astrocytoma or oligodendroglioma harbouring a susceptible IDH1 or IDH2 mutation, based on data from the INDIGO trial: fda.gov/drugs/resource…. Also see: nature.com/articles/s4157…

In a new Research Highlight now published online, we discuss the results of the E1910 trial testing addition of blinatumomab to consolidation chemotherapy in B cell-precursor acute lymphoblastic #leukemia nature.com/articles/s4157…

Yesterday, the FDA approved neoadjuvant/adjuvant durvalumab, plus neoadjuvant chemo, for resectable NSCLC, based on pCR (17% vs 4% with placebo plus chemo) & EFS (NR vs 25.9 months; HR 0.68, 95% CI 0.53-0.88; P=0.0039) data from the phase III AEGEAN trial: fda.gov/drugs/resource…

In a new Review now live online, Keri Toner, Chase McCann & Catherine Bollard discuss the 'Applications of cell therapy in the treatment of virus-associated cancers': nature.com/articles/s4157… #ImmunoOnc #hemeonc #caxtx #medonc

FDA approves lazertinib + amivantamab for the 1L treatment of advanced EGFR-mutant NSCLC based on data from the MARIPOSA trial: fda.gov/drugs/resource…. In a new article, Fatemeh Ardeshir-Larijani & Suresh Ramalingam discuss this trial & its implications: nature.com/articles/s4157…

In this new Review, Maxwell Lloyd, Komal Jhaveri, Kevin Kalinsky, Aditya Bardia & Seth Wander discuss 'Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer': nature.com/articles/s4157…

In this new Review, now live online, Jan Budczies, Albrecht Stenzinger and co-authors discuss the clinical utility, challenges and emerging improvements of tumour mutational burden as a predictive biomarker for immunotherapy: nature.com/articles/s4157…

In this new Review, Jeffrey How, Karen Lu and colleagues discuss the progress made in translating biological insights into improved management of endometrial cancer: nature.com/articles/s4157…

In a Comment now published live, Carolyn Taylor calls for #patients-centred research in #oncology You can read this article using this link rdcu.be/dSOeV nature.com/articles/s4157…

In this new Review, George Coukos and colleagues discuss immunotherapy for ovarian cancer and the move towards a tailored immunophenotype-based approach: nature.com/articles/s4157…

In a Comment now published online, Jana Lipkova and Jakob Nikolas Kather discuss the potential utility of the Virchow foundation model in #pathology nature.com/articles/s4157…